Additionally, since lactylation may regulate multiple immune checkpoints simultaneously, a multi-target approach combining anti-PD-1/PD-L1, anti-CTLA-4, and lactylation inhibitors may be necessary to overcome immune resistance in prostate cancer. The gene discussed is CTLA4; the disease is prostate carcinoma.